Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.
Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
| Iaith wreiddiol | Saesneg |
|---|---|
| Cyhoeddwr | Unknown |
| Corff comisiynu | Janssen Pharmaceutica |
| Argraffiad | 2002 |
| Statws | Cyhoeddwyd - 1 Ion 2002 |